GLP-1 drugs are shaking things up in the market! Novo Nordisk's Ozempic is a game-changer, showing early signs of helping diabetes patients' kidneys. This news made dialysis providers like DaVita (-17%) and Fresenius Medical (-17.6%) stocks drop big time.
Ironically, these drugs could keep folks on dialysis for longer, creating short-term chances for the providers. Plus, Novo's Ozempic is on fire and could help up to 5 million patients, which is negative for consumer snack companies.
Leave a Reply